- Home
- IMMP vs INZY Comparison
IMMP vs INZY Comparison
Compare IMMP & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- INZY
- Stock Information
- Founded
- IMMP 1987
- INZY 2015
- Country
- IMMP Australia
- INZY United States
- Employees
- IMMP N/A
- INZY N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- IMMP Health Care
- INZY Health Care
- Exchange
- IMMP Nasdaq
- INZY Nasdaq
- Market Cap
- IMMP 251.8M
- INZY 256.3M
- IPO Year
- IMMP N/A
- INZY 2020
- Fundamental
- Price
- IMMP $1.57
- INZY $3.99
- Analyst Decision
- IMMP Buy
- INZY Buy
- Analyst Count
- IMMP 1
- INZY 9
- Target Price
- IMMP $7.00
- INZY $15.22
- AVG Volume (30 Days)
- IMMP 111.5K
- INZY 1.3M
- Earning Date
- IMMP 02-27-2025
- INZY 08-05-2025
- Dividend Yield
- IMMP N/A
- INZY N/A
- EPS Growth
- IMMP N/A
- INZY N/A
- EPS
- IMMP N/A
- INZY N/A
- Revenue
- IMMP $3,019,249.00
- INZY N/A
- Revenue This Year
- IMMP $50.37
- INZY N/A
- Revenue Next Year
- IMMP N/A
- INZY N/A
- P/E Ratio
- IMMP N/A
- INZY N/A
- Revenue Growth
- IMMP 24.11
- INZY N/A
- 52 Week Low
- IMMP $1.32
- INZY $0.72
- 52 Week High
- IMMP $2.80
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- IMMP 36.75
- INZY 83.61
- Support Level
- IMMP $1.51
- INZY $3.94
- Resistance Level
- IMMP $1.63
- INZY $3.97
- Average True Range (ATR)
- IMMP 0.07
- INZY 0.01
- MACD
- IMMP -0.03
- INZY -0.10
- Stochastic Oscillator
- IMMP 14.34
- INZY 70.67
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.